Given that the present treatments for ULD are only symptomatic, these results suggest that splice-modifying AOs might be a potential alternative or adjunct treatment strategy for patients holding splicing changes in the CSTB gene. The gene discussed is CSTB; the disease is Unverricht-Lundborg syndrome.